National Health Institute Director Francis S. Collins served for 12 years under three presidents and presided over an expansion of the agency's budget and efforts to develop new cures to diseases. Graeme Jennings/POOL/AFP via Getty Images hide caption
National Health Institute Director Francis S. Collins served for 12 years under three presidents and presided over an expansion of the agency's budget and efforts to develop new cures to diseases.
It's Dr. Francis Collins' last few weeks as director of National Institutes of Health after 12 years, serving three presidents. Collins made his name doing the kind of biomedical research NIH is famous for, especially running The Human Genome Project, which fully sequenced the human genetic code. The focus on biomedicine and cures has helped him grow the agency's budget to over $40 billion a year and win allies in both political parties.
Still, in a broad sense, Americans' health hasn't improved much in those 12 years, especially compared to people in peer countries, and some have argued the agency hasn't done enough to try to turn these trends around. One recently retired NIH division director has quipped that one way to increase funding for this line of research would be if "out of every $100 dollars, $1 would be put into the 'Hey, how come nobody's healthy?' fund."
In a wide-ranging conversation, Collins answers NPR's questions as to why for all the taxpayer dollars going to NIH research there haven't been more gains when it comes to Americans' overall health. He also talks about how tribalism in American culture has fueled vaccine hesitancy, and he advises his successor on how to persevere on research of politically charged topics like guns and obesity and maternal health even if powerful lobbies might want that research not to get done.
This interview has been edited for length and clarity.
Selena Simmons-Duffin: After you announced you'd be stepping down from the director role, you told the New York Times that one of your "chief regrets" was the persistence of vaccine hesitancy during the pandemic. How are you thinking about the role NIH could play in understanding this problem?
Francis Collins: I do think we need to understand better how in the current climate people make decisions. I don't think I anticipated the degree to which the tribalism of our current society would actually interfere with abilities to size up medical information and make the kinds of decisions that were going to help people.
To have now 60 million people still holding off of taking advantage of life saving vaccines is pretty unexpected. It does make me, at least, realize, boy, there are things about human behavior that I don't think we had invested enough into understanding. We basically have seen accurate medical information overtaken, all too often, by the inaccurate conspiracies and false information on social media. It's a whole other world out there. We used to think that if knowledge was made available from credible sources, it would win the day. That's not happening now.
So you mentioned the idea of investing more in the behavioral research side of things. Do you think that should happen?
We're having serious conversations right now about whether this ought to be a special initiative at NIH to put more research into health communications and how best to frame those [messages] so that they reach people who may otherwise be influenced by information that's simply not based on evidence. Because I don't think you could look at the current circumstance now and say it's gone very well.
Looking at how America has fared in the pandemic more broadly, it really is astoundingly bad. The cases and deaths are just so high. CDC Director Robert Redfield, when he was leaving, told NPR he thought the baseline poor health of Americans had something to do with how powerfully the pandemic has hit America. What do you think about the toll of the pandemic, even as it's clearly not over?
It's a terrible toll. We've lost almost 800,000 lives. In 2020, before we had vaccines, there was not a really good strategy to protect people other than social distancing and mask-wearing, which were important, but certainly not guarantees of safety. And yes, it is the case that the people who got hit hardest, oftentimes, were people with underlying medical conditions.
But in 2021, we should have been better off. We had vaccines that were safe, that were available for free to all Americans. The ability to get immunized really went up very steeply in March and April, and yet it all kind of petered out by about May or June. The [vaccine] resistant group of 60 million people remains, for the most part, still resistant. Unfortunately, now, with delta having come along as a very contagious variant and with omicron now appearing, which may also be a real threat, we have missed the chance to put ourselves in a much better place.
Let's step back from the pandemic. In your 12 years as director, the NIH has worked on developing cures and getting them from the lab to patients faster, and the agency's budget has grown.
But, in that time, Americans haven't, on a broader scale, gotten healthier. They're sicker than people in other countries across the board, all races and incomes. When you were sworn in in 2009, life expectancy was 78.4 years, and it's been essentially stuck there.
Does it bother you that there haven't been more gains? And what role should NIH play in understanding these trends and trying to turn them around?
Well, sure, it does bother me. In many ways, the 28 years I have been at NIH have just been an amazing ride of discoveries upon discoveries. But you're right, we haven't seen that translate necessarily into advances.
Let's be clear, there are some things that have happened that are pretty exciting. Cancer deaths are dropping every year by one or two percent. When you add that up over 20 years, cancer deaths are down by almost 25% from where they were at the turn of the century. And that's a consequence of all the hard work that's gone into developing therapeutics based on genomics, as well as immunotherapy that's made a big dent in an otherwise terrible disease.
But we've lost ground in other areas, and a lot of them are a function of the fact that we don't have a very healthy lifestyle in our nation. Particularly with obesity and diabetes, those risk factors have been getting worse instead of better. We haven't, apparently, come up with strategies to turn that around.
On top of that, the other main reason for seeing a drop in life expectancy other than obesity and COVID is the opioid crisis. We at NIH are working as fast and as hard as we can to address that by trying to both identify better ways to prevent and treat drug addiction, but also to come up with treatments for chronic pain that are not addictive. Because those 25 million people who suffer from chronic pain every day deserve something better than a drug that is going to be harmful.
In all of these instances, as a research enterprise because that's our mandate it feels like we're making great progress. But the implementation of those findings runs up against a whole lot of obstacles, in terms of the way in which our society operates, in terms of the fact that our health care system is clearly full of disparities, full of racial inequities. We're not at NIH able to reach out and fix that, but we can sure shine a bright light on it and we can try to come up with pilot interventions to see what would help.
A 300-page report called "Shorter Lives, Poorer Health" came out in 2013 it was requested and financed by NIH and conducted by a National Academies of Science, Engineering and Medicine panel. It documented some of the things you just talked about, in terms of how Americans' health falls short compared to other countries. And it is filled with recommendations for further research, many specifically for NIH, including looking to how other countries are achieving better health outcomes than the U.S.
I'm curious, since this report came out when you were director, if it made an impact at the agency and whether there's been any progress on those recommendations or was a decision not to pursue those ideas?
I do remember that report and there have been a lot of other reports along the lines since then that have tried to point to things that other countries may be doing better than we are. One of the things I've tried to do is to provide additional strength and resources to our Office of Disease Prevention, because that's a lot of what we're talking about here. One of the knocks against the National Institutes of Health is that we often seem to be the National Institutes of Disease that a lot of the focus has been on people who are already diagnosed with some kind of health condition. And yet what we really want to do is to extend health span, not just lifespan, and that means really putting more research efforts into prevention.
One of the things that I'm excited about in that regard is the All of Us study, which is in the process of enrolling a million Americans, following them prospectively, many of them currently healthy. They share their electronic health records, they have blood samples taken that measure all kinds of things, including their complete genome sequences; they answer all kinds of questionnaires, they walk around with various kinds of wearable sensors. That's going to be a database that gives us information about exactly what's happened to the health of our nation and what could we do about it.
You've served under both Democratic and Republican administrations. One thing you've talked about in interviews is the culture wars. What role do you think NIH has to play in terms of developing trust and trying to get past some of that tribalism that you talked about before?
I think medical research should never be partisan. It should never get caught up in culture wars or tribal disagreements. But in our current society, it's hard to think of anything that hasn't at least been touched by those attitudes.
My goal as NIH director over these 12 years, serving three presidents, was to always try to keep medical research in a place that everybody could look at objectively and not consider it to be tainted in some way by political spin. I've made friends in Congress in both parties and both houses, in a way that I think has really helped the view of medical research to remain above the fray. And many of the strongest supporters for medical research over these 12 years have been in the Republican Party.
This is not something that people can really disagree about. You want to find answers to medical problems that are threatening yourself or your family or your community or your constituents. So I don't have a hard job in terms of explaining the mission or why we work so hard at what we do.
But I do have to sometimes worry that for whatever reason, politics will creep into this. And certainly with COVID, politics has crept into the space of misinformation in a fashion that has not helped with vaccine hesitancy. Frankly, I think it's pretty shameful if political figures trying to score points or draw attention to themselves put forward information about COVID that's demonstrably false.
Some of the reasons why Americans tend to be less healthy than people in other countries can get political pretty quickly like healthy environments and gun injuries and drug overdoses and maternal health. But the research is important.
Do you have any guidance or thoughts for your successor on how to support the kind of research that's not as universally embraced on both sides of the aisle?
I think the guidance is you have to look at all the reasons why people are not having a full life experience of health and figure out what we, as the largest supporter of medical research in the world, should be doing to try to understand and change those circumstances. A lot of this falls into the category of health disparities. It is shameful that your likelihood of having a certain lifespan depends heavily on the zip code where you were born, and that is a reflection of all of the inequities that exist in our society in terms of environmental exposures, socioeconomics, social determinants of health, et cetera.
We are ramping up that effort right now, especially not just to observe the situation or, as some cynics have said, admire the situation. We actually want to try pilot interventions to see if some of those things can be changed. But that's about as far as we can go. Again, if there's a major societal illness right now of tribalism and over-polarization and hyper-partisanship about every issue, probably the NIH is not well positioned all by ourselves to fix that. We have an urgent need, I think, across society, to recognize that we may have lost something here our anchor to a shared sense of vision and a shared sense of agreement about what is truth.
You are leaving this post. Where do you imagine the agency might go next? I know you're still going to be doing your work on Type 2 diabetes you'll still be a part of it. So what do you see in NIH's future?
I think it is in a remarkably positive place right now as far as what we are called to do, which is to make discoveries, to learn about how life works and then apply that in a way that will lead to answers for diseases that currently don't have them. I think of NIH as not just the National Institutes of Health, but the National Institutes of Hope, and we are able now to provide hope for lots of situations that previously couldn't have really been confident in that. Look what's happened in terms of gene therapies we're curing sickle cell disease now, something I thought would never happen in my lifetime, with gene therapies. Look at what we're able to do with cancer immunotherapy, saving people who have stage IV disease, in certain circumstances, by activating the immune system. And of course, in infectious diseases not only have we now got mRNA vaccines for the terrible COVID-19 situation, we can apply those to lots of other infections as well.
So, anybody listening to this who's thinking maybe of moving into a career in biomedical research, this is the golden era and we need all the talent and the vision that we can possibly recruit into our midst because it's going to be a grand adventure in the coming decades.
Read the original here:
Francis Collins on medical advances, vaccine hesitancy and Americans' ill health : Shots - Health News - NPR
- BENITEC BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - February 13th, 2023 [February 13th, 2023]
- CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day - Marketscreener.com - February 7th, 2023 [February 7th, 2023]
- Gene | Definition, Structure, Expression, & Facts | Britannica - January 27th, 2023 [January 27th, 2023]
- New gene therapy delivers treatment directly to brain - January 27th, 2023 [January 27th, 2023]
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 25th, 2023 [January 25th, 2023]
- A blood test that identifies people at higher risk of miscarriage? Thats the goal of this award-winning Rutgers med student. - The Philadelphia... - January 19th, 2023 [January 19th, 2023]
- Gene Therapy: Genes As Medicine | Pfizer - January 6th, 2023 [January 6th, 2023]
- How Genomics will ensure a risk-free and beneficial treatment for good health and well-being - The Financial Express - December 28th, 2022 [December 28th, 2022]
- Regenerative Medicine Advanced Therapy Designation | FDA - December 18th, 2022 [December 18th, 2022]
- 3576 - Gene ResultCXCL8 C-X-C motif chemokine ligand 8 [ (human)] - November 23rd, 2022 [November 23rd, 2022]
- Study identifies new gene that drives colon cancer - EurekAlert - October 17th, 2022 [October 17th, 2022]
- Updated Stroke Gene Panels: Rapid evolution of knowledge on monogenic causes of stroke | European Journal of Human Genetics - Nature.com - October 17th, 2022 [October 17th, 2022]
- The challenges of translating CRISPR to the clinic - Labiotech.eu - October 17th, 2022 [October 17th, 2022]
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 17th, 2022 [October 17th, 2022]
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 17th, 2022 [October 17th, 2022]
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 17th, 2022 [October 17th, 2022]
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 17th, 2022 [October 17th, 2022]
- CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual... - October 17th, 2022 [October 17th, 2022]
- Depression Treatment: How Genetic Testing Can Help Find the Right Medication - Dunya News - October 17th, 2022 [October 17th, 2022]
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 17th, 2022 [October 17th, 2022]
- Precision Medicine Could Get Even More Precise With Allarity Therapeutics Next-Generation Diagnostics - Benzinga - October 17th, 2022 [October 17th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 17th, 2022 [October 17th, 2022]
- Time for your medicine: unlocking the power of our body clocks - The Guardian - October 17th, 2022 [October 17th, 2022]
- Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- Scientists Reappraise the Role of Zombie Cells That Anti-aging Medicine Has Sought to Eliminate - Neuroscience News - October 17th, 2022 [October 17th, 2022]
- Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease - Business... - October 17th, 2022 [October 17th, 2022]
- Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC - Targeted Oncology - October 17th, 2022 [October 17th, 2022]
- NHS England World-first national genetic testing service to deliver rapid life-saving checks for babies and kids - NHS England - October 17th, 2022 [October 17th, 2022]
- The proteinprotein relationship that could mend a broken heart - RegMedNet - October 17th, 2022 [October 17th, 2022]
- Study finds microprotein correlated to Alzheimers risk - Daily Trojan Online - October 11th, 2022 [October 11th, 2022]
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance - October 11th, 2022 [October 11th, 2022]
- Gene Therapy Rapidly Improves Night Vision in Adults with Congenital Blindness - Newswise - October 11th, 2022 [October 11th, 2022]
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- The Pros and Cons of Lentiviral and Adeno-Associated Viral Vectors - The Medicine Maker - October 11th, 2022 [October 11th, 2022]
- Insights & Outcomes: Foreign DNA, quantum potholes and relapsing fever - Yale News - October 11th, 2022 [October 11th, 2022]
- Expediting IND applications with drug master files - BioPharma Dive - October 11th, 2022 [October 11th, 2022]
- UNC School of Medicine Awarded $3 Million to Lead Study to Reduce PTSD Frequency, Severity | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa - businesswire.com - October 8th, 2022 [October 8th, 2022]
- The Next Crispr Gene Editing IPO Could Be Near - Henry Herald - October 8th, 2022 [October 8th, 2022]
- 10-year CRISPR anniversary: How gene editing revolutionized medicine, and what lies ahead - Genetic Literacy Project - October 8th, 2022 [October 8th, 2022]
- Blood from a baby at birth can be gene sequenced to prevent diseases - USA TODAY - October 8th, 2022 [October 8th, 2022]
- What doctors wish patients knew about breast-cancer prevention - American Medical Association - October 8th, 2022 [October 8th, 2022]
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 8th, 2022 [October 8th, 2022]
- Gene Editing Service Market 2022 : Top Players to Reflect Impressive Growth Rate till 2029: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA,... - October 8th, 2022 [October 8th, 2022]
- Tip Sheet: $78 million to support new precision oncology institute, update on experimental gene therapy for herpes and the launch of Fred Hutch's new... - October 8th, 2022 [October 8th, 2022]
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 2nd, 2022 [October 2nd, 2022]
- Growth in Cell and Gene Therapy Market - BioPharm International - October 2nd, 2022 [October 2nd, 2022]
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 2nd, 2022 [October 2nd, 2022]
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 2nd, 2022 [October 2nd, 2022]
- Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine - October 2nd, 2022 [October 2nd, 2022]
- This gene therapy company is testing new tech to 'switch off' diabetes and obesity with a pill - Euronews - October 2nd, 2022 [October 2nd, 2022]
- Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Risk of Alzheimer's dementia may be predicted with help of new tool Washington University School of Medicine in St. Louis - Washington University... - October 2nd, 2022 [October 2nd, 2022]
- Tiny Sea Creature's Genes Shed Light on Evolution of Immunity - UPMC - October 2nd, 2022 [October 2nd, 2022]
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 2nd, 2022 [October 2nd, 2022]
- Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as... - October 2nd, 2022 [October 2nd, 2022]
- NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy - Neurology Live - October 2nd, 2022 [October 2nd, 2022]
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 2nd, 2022 [October 2nd, 2022]
- Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments - University of Alabama at Birmingham - October 2nd, 2022 [October 2nd, 2022]
- Nobel Prize for medicine: the full list of winners - The National - October 2nd, 2022 [October 2nd, 2022]
- The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert - October 2nd, 2022 [October 2nd, 2022]
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector Compositions - Yahoo Finance - September 20th, 2022 [September 20th, 2022]
- Cholesterol gene mutation: Why would a healthy 27-year-old have severe heart problems? - 69News WFMZ-TV - September 20th, 2022 [September 20th, 2022]
- Gene Therapy for Severe Hemophilia B Could Be More Cost Effective Than Current Treatments - Managed Healthcare Executive - September 20th, 2022 [September 20th, 2022]
- AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis... - September 20th, 2022 [September 20th, 2022]
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 20th, 2022 [September 20th, 2022]
- Leading Virus Researcher to Chair UVA's Department of Microbiology, Immunology and Cancer Biology - UVA Health Newsroom - September 20th, 2022 [September 20th, 2022]
- Work remains on Tay-Sachs and other Ashkenazi genetic disorders J. - The Jewish News of Northern California - September 20th, 2022 [September 20th, 2022]
- Study Shows Genetic Link to Moving to the Beat of Music - Newswise - September 20th, 2022 [September 20th, 2022]
- Viewpoint: In the post Roe v Wade world, what changes should a biology textbook writer make to address the medical repercussions of Dobbs? - Genetic... - September 20th, 2022 [September 20th, 2022]
- Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult... - September 20th, 2022 [September 20th, 2022]
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 20th, 2022 [September 20th, 2022]
- The MIT Press releases new book on the science of the heart from cardiac expert Dr. Sian Harding - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo... - September 20th, 2022 [September 20th, 2022]
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801... - September 20th, 2022 [September 20th, 2022]
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A 'Practice Changing' Trial -... - September 20th, 2022 [September 20th, 2022]
- Getting rid of unwanted transformed cells: Possible new directions in cancer therapy - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Sven Kili on reconvening with the ISCT - The Medicine Maker - September 14th, 2022 [September 14th, 2022]